Stuttgart - Delayed Quote EUR

SI-BONE Inc (2K3.SG)

12.60

0.00

(0.00%)

At close: April 25 at 9:46:58 PM GMT+2

SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.

GlobeNewswire 11 days ago

SIBN
IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?

IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 15 days ago

IQV

SIBN
SI-Bone price target raised to $24 from $20 at Needham

Needham analyst David Saxon raised the firm’s price target on SI-Bone (SIBN) to $24 from $20 and keeps a Buy rating on the shares. The company’s Q4 revenue was in line with its pre-announcement as procedure volume growth improved from the prior quarter and SI-Bone’s active surgeon base reached another record, the analyst tells investors in a research note. The management also guided to adjusted EBITDA profitability for 2025, the firm adds. Published first on TheFly – the ultimate source for real

TipRanks last month

SIBN
SI-BONE Full Year 2024 Earnings: EPS Beats Expectations

SI-BONE ( NASDAQ:SIBN ) Full Year 2024 Results Key Financial Results Revenue: US$167.2m (up 20% from FY 2023). Net...

Simply Wall St. last month

SIBN
Q4 2024 SI-BONE Inc Earnings Call

Q4 2024 SI-BONE Inc Earnings Call

Thomson Reuters StreetEvents last month

SIBN
SI-BONE Inc (SIBN) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Positive EBITDA

SI-BONE Inc (SIBN) reports a robust 26% revenue growth in Q4 2024, achieving positive adjusted EBITDA and setting optimistic guidance for 2025.

GuruFocus.com last month

SIBN
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 0.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

SIBN
Si-Bone: Q4 Earnings Snapshot

SIBN) on Monday reported a loss of $4.5 million in its fourth quarter. On a per-share basis, the Santa Clara, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations.

Associated Press Finance last month

SIBN
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26% U.S. revenu

GlobeNewswire last month

SIBN
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

SIBN

GMED
SI-BONE (NASDAQ:SIBN) shareholders have endured a 20% loss from investing in the stock five years ago

SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders should be happy to see the share price up 19% in the last month. But if you...

Simply Wall St. 2 months ago

SIBN
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at t

GlobeNewswire 2 months ago

SIBN
SI-Bone price target raised to $20 from $19 at Needham

Needham raised the firm’s price target on SI-Bone (SIBN) to $20 from $19 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin

TipRanks 3 months ago

SIBN
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons are to the prior year per

GlobeNewswire 3 months ago

SIBN
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 4 months ago

SIBN
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?

The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 4 months ago

SIBN
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: ht

GlobeNewswire 5 months ago

SIBN
SI-BONE, Inc. (NASDAQ:SIBN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

There's been a major selloff in SI-BONE, Inc. ( NASDAQ:SIBN ) shares in the week since it released its quarterly...

Simply Wall St. 5 months ago

SIBN
SI-BONE Third Quarter 2024 Earnings: EPS Beats Expectations

SI-BONE ( NASDAQ:SIBN ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.3m (up 19% from 3Q 2023). Net...

Simply Wall St. 5 months ago

SIBN
Q3 2024 SI-BONE Inc Earnings Call

Q3 2024 SI-BONE Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

SIBN

Performance Overview

Return	2K3.SG	S&P 500 (^GSPC)
YTD	-3.08%	-6.06%
1-Year	-3.82%	+9.44%
3-Year	-27.17%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SI-BONE Inc (2K3.SG)

SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?

SI-Bone price target raised to $24 from $20 at Needham

SI-BONE Full Year 2024 Earnings: EPS Beats Expectations

Q4 2024 SI-BONE Inc Earnings Call

SI-BONE Inc (SIBN) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Positive EBITDA

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone: Q4 Earnings Snapshot

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?

SI-BONE (NASDAQ:SIBN) shareholders have endured a 20% loss from investing in the stock five years ago

SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

SI-Bone price target raised to $20 from $19 at Needham

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade

Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?

SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

SI-BONE, Inc. (NASDAQ:SIBN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

SI-BONE Third Quarter 2024 Earnings: EPS Beats Expectations

Q3 2024 SI-BONE Inc Earnings Call

Performance Overview